Crisp Therapeutics AG

CRSP

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001674416

A

strongest fifth of 370 graded peers in healthcare

rank 23 of 370; percentile 6.0; sampling error 2.5 points; lower is stronger



A, the bull



Scoreboard	
Profitability	B/C percentile 39.7
Solvency	A percentile 13.7
Growth and financing	B/C percentile 39.9
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $2.3B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Feb 12, 2026 268 days before the rescan; latest periodic filing 10-Q received Nov 2, 2026
Last close	$50.08 2026-11-06; market equity $4.9B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 12, 2026

Our mission is to create transformative gene-based medicines for serious human diseases. We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology. CRISPR/Cas9 is a revolutionary technology for gene editing, the process of precisely altering specific sequences of genomic DNA. We have advanced this technology from discovery to an approved medicine with unparalleled speed, culminating in the landmark first approval of a CRISPR-based therapy, CASGEVY (exagamglogene autotemcel [exa-cel]), in 2023 with our collaborators at Vertex Pharmaceuticals Incorporated, or Vertex.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 39.7						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.3%			
one or more required annual facts are missing					
Accruals ratio	(10.5%)	(6.6%)	39.7	802	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 13.7					
Twelve-month failure probability	0.03%	0.08%	16.1	249	2026-09-30
Altman Z double-prime	6.42	(0.37)	15.1	747	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	13.32x	2.94x	9.7	828	2025-12-31
Growth and financing, sleeve percentile 39.9					
Revenue growth, three-year compound	43.1%	10.0%	15.6	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	0.3%	2.2%	51.4	696	2025-12-31
Net share issuance, one year	11.9%	2.5%	52.8	630	2026-02-10

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
18	Intuitive Surgical Inc. (ISRG)	4.6	A	
19	Vericel Corp. (VCEL)	4.9	A	
20	SBC Medical Group Holdings Inc. (SBC)	5.3	A	fortress balance sheet
21	SBC Medical Group Holdings Inc. (SBCWW)	5.3	A	fortress balance sheet
22	Neurocrine Biosciences Inc. (NBIX)	5.7	A	
23	Crispr Therapeutics AG (CRSP)	6.0	A	
24	Ideaya Biosciences, Inc. (IDYA)	6.2	A	
25	AtriCure, Inc. (ATRC)	6.5	A	
26	United Therapeutics Corp. (UTHR)	6.8	A	
27	Gyre Therapeutics, Inc. (GYRE)	7.0	A	fortress balance sheet
28	Hims & Hers Health, Inc. (HIMS)	7.3	A	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(13.5%)	(2.1%)	41
Distance from 52-week high	(19.1%)	(30.5%)	63
EBIT to enterprise value	(12.7%)	(1.5%)	30
Free cash flow yield	(7.1%)	(1.0%)	38
Book value to price	0.34	0.29	55
Sales to price	0.00	0.30	3
Composite equity issuance, five years	25.2%	21.4%	52
Relative strength against the sector, log excess return	(0.31)	(0.19)	41

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$192.0M
Operating cash flow, four quarters	-$374.6M
Months of runway	6.2
Days since last periodic filing	5 (10-Q received Nov 2, 2026)
Median daily dollar volume, 63 sessions	$69.6M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$581.6M	2025-12-31	2026-02-12	10-K	26-048957
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$345.0M	2025-12-31	2026-02-12	10-K	26-048957
3	assets	us-gaap:Assets	$2.3B	2025-12-31	2026-02-12	10-K	26-048957
4	assets	us-gaap:Assets	$2.2B	2024-12-31	2026-02-12	10-K	26-048957
5	current assets	us-gaap:AssetsCurrent	$2.0B	2025-12-31	2026-02-12	10-K	26-048957
6	current liabilities	us-gaap:LiabilitiesCurrent	$149.1M	2025-12-31	2026-02-12	10-K	26-048957
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.9B	2025-12-31	2026-02-12	10-K	26-048957
8	operating income	us-gaap:OperatingIncomeLoss	-$664.6M	2025-12-31	2026-02-12	10-K	26-048957
9	book equity	us-gaap:StockholdersEquity	$1.9B	2025-12-31	2026-02-12	10-K	26-048957
10	liabilities	us-gaap:Liabilities	$343.4M	2025-12-31	2026-02-12	10-K	26-048957
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.5M	2025-12-31	2026-02-12	10-K	26-048957
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$37.3M	2024-12-31	2026-02-12	10-K	26-048957
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$371.2M	2023-12-31	2026-02-12	10-K	26-048957
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.2M	2022-12-31	2025-02-11	10-K	25-017899
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$914,000	2025-12-31	2026-02-12	10-K	26-048957
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$142.8M	2024-12-31	2026-02-12	10-K	26-048957
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.9M	2024-12-31	2026-02-12	10-K	26-048957
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$260.4M	2023-12-31	2026-02-12	10-K	26-048957

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$9.5M	2023-12-31	2026-02-12	10-K	26-048957
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$495.7M	2022-12-31	2025-02-11	10-K	25-017899
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$37.2M	2022-12-31	2025-02-11	10-K	25-017899
22	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$19.5M	2025-12-31	2026-02-12	10-K	26-048957
23	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$578.0M	2025-12-31	2026-02-12	10-K	26-048957
24	income tax	us-gaap:IncomeTaxExpenseBenefit	$3.6M	2025-12-31	2026-02-12	10-K	26-048957
25	current assets	us-gaap:AssetsCurrent	$1.9B	2024-12-31	2026-02-12	10-K	26-048957
26	current liabilities	us-gaap:LiabilitiesCurrent	$87.8M	2024-12-31	2026-02-12	10-K	26-048957
27	assets	us-gaap:Assets	$2.2B	2023-12-31	2025-02-11	10-K	25-017899
28	assets	us-gaap:Assets	$2.2B	2022-12-31	2024-02-21	10-K	24-017571
29	shares outstanding	dei:EntityCommonStockSharesOutstanding	95,985,312	2026-02-10	2026-02-12	10-K	26-048957
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	85,774,474	2025-02-07	2025-02-11	10-K	25-017899

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.